C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting

AIDS

Volumn 21, Issue 15, 2007, Pages 2067-2075

  Drain, Paul K ^a,d,e   Kupka, Roland ^b   Msamanga, Gernard I ^c   Urassa, Willy ^c   Mugusi, Ferdinand ^c   Fawzi, Wafaie W ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

C reactive protein; Disease progression; HIV AIDS; Mortality; Mother to child transmission; Resource poor setting

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN;

ADULT; ANTHROPOMETRY; ARTICLE; BIRTH; CD4+ T LYMPHOCYTE; CHILDHOOD MORTALITY; CONFIDENCE INTERVAL; DEATH; DEMOGRAPHY; DISEASE COURSE; FEMALE; FETUS OUTCOME; HEALTH CARE AVAILABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MATERNAL DISEASE; MATERNAL MORTALITY; MULTIVARIATE ANALYSIS; NEWBORN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; STATISTICAL MODEL; VERTICAL TRANSMISSION; VIRUS LOAD;

C-REACTIVE PROTEIN; CHILD MORTALITY; CHILD, PRESCHOOL; DISEASE PROGRESSION; DISEASE TRANSMISSION, VERTICAL; FEMALE; FOLLOW-UP STUDIES; HEALTH RESOURCES; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT MORTALITY; MATERNAL MORTALITY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROGNOSIS; TANZANIA;

EID: 34648831475     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32826fb6c7     Document Type: Article

References (43)

1. Rabkin M, El-Sadr W, Katzenstein DA, Mukherjee J, Masur H, Mugyenyi P, et al. Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet 2002; 360:1503-1505.
2. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-454.
3. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349:462-466.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979; [erratum, N Engl J Med 1997; 337:356].
5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
6. Falconer JS, Fearon KCH, Ross JA, Elson R, Wigmore SJ, Garden OJ, et al. Acute phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995; 75:2077-2082.
7. Sattar N, McMillan DC. Association between plasminogen activator inhibitor-1 and survival in colorectal cancer: measuring C-reactive protein may be more useful. BMJ 1998; 317:750-2751.
8. Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii Pneumonia in Immuno-compromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002; 21:523-531.
9. Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006; 166:64-70.
10. Melchior JC, Niyongabo T, Henzel D, Durack-Bown I, Henri SC, Boulier A. Malnutrition and wasting, immunodepression, and chronic inflammation as independent predictors of survival in HIV-infected patients. Nutrition 1999; 15:865-869.
11. Feldman JG, Goldwasser P, Holman S, DeHovitz J, Minkoff H. C-Reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr 2003; 32:210-214.
12. Grutzmeier S, Sandstrom E. C-reactive protein levels in HIV complicated by opportunistic infections and infections with common bacterial pathogens. Scand J Infect Dis 1999; 31:229-234.
13. Fawzi WW, Msamanga GI, Spiegelman D, Urassa EJ, Hunter DJ. Rationale and design of the Tanzania Vitamin and HIV Infection Trial. Control Clin Trials 1999; 20:75-90.
14. Young B, Gleeson M, Cripps AW. C-reactive protein: a critical review. Pathology 1991; 23:118-124.
15. Fawzi WW, Msamanga G, Hunter D, Renjifo B, Antelan G, Bang H, et al. Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality. AIDS 2002; 16:1935-1944.
16. Fawzi WW, Msamanga GI, Spiegelman D, Wei R, Kapiga S, Villamor E, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004; 351:23-32.
17. Volanakis JE. Acute phase proteins in rheumatic disease. In: Arthritis and allied conditions: a textbook of rheumatology, 13th edn.. Edited by Koopman WJ. Baltimore: Lippincott Williams & Wilkins; 1997. pp. 505-514.
18. Noursadeghi M, Miller RF. Clinical value of C-reactive protein measurements in HIV-positive patients. Int J STD & AIDS 2005; 16:438-441.
19. Schleicher GK, Herbert V, Brink A, Martin S, Maraj R, Galpin JS, et al. Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J 2005; 25:688-692.
20. Lala SG, Madhi SA, Pettifor JM. The discriminative value of C-reactive protein levels in distinguishing between community-acquired bacteraemic and respiratory virus-associated lower respiratory tract infections in HIV-1-infected and - uninfected children. Ann Trop Paediatr 2002; 22:271-279.
21. Lawn SD, Wiktor S, Coulibaly D, Ackah AN, Lal RB. Serum C-reactive protein and detection of tuberculosis in persons co-infected with the human immunodeficiency virus. Trans R Soc Trop Med Hyg 2001; 95:41-42.
22. Storgaard M, Laursen AL, Andersen PL. The C-reactive protein responses in HIV-infected patients with pneumonia. Scand J Infect Dis 1993; 25:305-309.
23. Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci 1982; 389:406-418.
24. Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P, Feingold KR. Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 1992; 55:455-460.
25. Godfried MH, van der Poll T, Jansen J, Romijin JA, Schattenkerk JK, Endert E, et al. Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection. AIDS 1993; 7:33-36.
26. Belec L, Meillet D, Hernvann A, Gresenguet G, Gherardi R. Differential elevation of circulating interleukin-1β, tumor necrosis factor alpha, and interleukin-6 in AIDS-associated cachectic states. Clin Diag Lab Immun 1994; 1:117-120.
27. Rimaniol AC, Zylberberg H, Zavala F, Viard JP. Inflammatory cytokines and inhibitors in HIV infection: correlation between interleukin-1 receptor antagonist and weight loss. AIDS 1996; 10:1349-1356.
28. Wheeler DA, Gibert CL, Launer CA, Muurahainen N, Elion RA, Abrams DI, et al. Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:80-85.
29. Jones CY, Hogan JW, Snyder B, Klein RS, Rompalo A, Schuman P, et al. Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort. Clin Infect Dis 2003; 37 (suppl 2):S69-S80.
30. Ford ES, Liu S, Mannino DM, Giles WH, Smith SJ. C-reactive protein concentrations and concentrations of blood vitamins, carotenoids, and selenium among United States adults. Eur J Clin Nutr 2003; 57:1157-1163.
31. Maehira F, Luyo GA, Miyagi I, Oshiro M, Yamane N, Kuba M, et al. Alterations of serum seleniumconcentrations in the acute phase of pathological conditions. Clin Chim Acta 2002; 316:137-146.
32. Ghayour-Mobarhan M, Taylor A, New SA, Lamb DJ, Ferns GA. Determinants of serum copper, zinc, and selenium in healthy subjects. Ann Clin Biochem 2005; 42:364-375.
33. Koyanagi A, Kuffo D, Gresely L, Shenkin A, Cuevas LE. Relationships between serum concentrations of C-reactive protein and micronutrients, in patients with tuberculosis. Ann Trop Med Parasitol 2004; 98:391-399.
34. Baeten JM, McClelland RS, Richardson BA, Bankson DD, Lavreys L, Wener MH, et al. Vitamin A deficiency and the acute phase response among HIV-1-infected and -uninfected women in Kenya. J Acquir Immune Syndr 2002; 31:243-249.
35. Look MP, Rockstroch JK, Rao GS, Kreuzer KA, Barton S, Lemoch H, et al. Serum selenium versus lymphocyte subsets and markers of disease progression and inflammatory response in human immunodeficiency virus-infection. Biol Trace Elem Res 1997; 56:31-41.
36. Semba RD, Tang AM. Micronutrients and the pathogenesis of human immunodeficiency virus infection. Br J Nutr 1999; 81:181-189.
37. Kupka R, Fawzi W. Zinc nutrition and HIV infection. Nutr Rev 2002; 60:69-79.
38. Pitt J, Henrard D, FitzGerald G, Mofenson L, Lew J, Hillyer G, et al. Human immunodeficiency virus (HIV) type 1 antibodies in perinatal HIV-1 infection: Association with human HIV-1 transmission, infection, and disease progression. For the Women and Infants Transmission Study. J Infect Dis 2000; 182:1243-1246.
39. Fawzi WW, Msamanga GI, Wei R, Spiegelman D, Antelman G, Villamor E, et al. Effect of providing vitamin supplements to human immunodeficiency virus-infected, lactating mothers on the child's morbility and CD4R cell counts. Clin Infect Dis 2003; 36:1053-1062.
40. Kuhn L, Kasonde P, Sinkala M, Kankasa C, Semrau K, Scott N, et al. Does severity of HIV disease in HIV-infected mothers affect mortality and morbidity among their uninfected infants? Clin Infect Dis 2005; 41:1654-1661.
41. Stephensen CB, Marquis GS, Douglas SD, Wilson CM. Immune activation and oxidative damage in HIV-positive and HIV-negative adolescents. J Acquir Immune Defic Syndr 2005; 38:180-190.
42. Henry K, Kitch D, Dube M, Zackin R, Parker RA, Sprecher D, et al. C-reactive protein levels over time and cardiovascular risk in HIV-infected individuals on an indinivir-based regimen: AIDS Clinical Trials Group 5056s. AIDS 2004; 18:2434-2437.
43. Heggelund L, Mollnes TE, Ueland T, Christophersen B, Aukrust P, Froland SS. Mannose-binding lectin in HIV infection: relation to disease progression and highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 32:354-361.